Creo Medical Group (LON:CREO) Given “House Stock” Rating at Shore Capital Group

Shore Capital Group reaffirmed their house stock rating on shares of Creo Medical Group (LON:CREO) in a research note published on Thursday morning,Digital Look reports.

Creo Medical Group Stock Up 0.6%

CREO opened at GBX 11.83 on Thursday. Creo Medical Group has a one year low of GBX 9.22 and a one year high of GBX 18.50. The company has a debt-to-equity ratio of 6.90, a quick ratio of 2.19 and a current ratio of 5.28. The stock’s fifty day moving average is GBX 13.68 and its 200-day moving average is GBX 12.01. The company has a market capitalization of £48.77 million, a PE ratio of -11.83 and a beta of 1.22.

Creo Medical Group Company Profile

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.